Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer

Oncotarget

Volumn 7, Issue 25, 2016, Pages 37839-37845

  Salvi, Samanta ^a   Casadio, Valentina ^a   Conteduca, Vincenza ^a   Lolli, Cristian ^a   Gurioli, Giorgia ^a   Martignano, Filippo ^a,b   Schepisi, Giuseppe ^a   Testoni, Sara ^a   Scarpi, Emanuela ^a   Amadori, Dino ^a   Calistri, Daniele ^a   Attard, Gerhardt ^c   de Giorgi, Ugo ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Androgen receptor; Circulating cell free DNA; Copy number variation; Enzalutamide; Prostate cancer

Indexed keywords

ALKALINE PHOSPHATASE; ANDROGEN RECEPTOR; DOCETAXEL; ENZALUTAMIDE; LACTATE DEHYDROGENASE; PROSTATE SPECIFIC ANTIGEN; AR PROTEIN, HUMAN; DNA; PHENYLTHIOHYDANTOIN; TAXOID; TUMOR MARKER;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AR GENE; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; COHORT ANALYSIS; CONTROLLED STUDY; GENE DOSAGE; GENETIC ASSOCIATION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; VERY ELDERLY; ANALOGS AND DERIVATIVES; BLOOD; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; DNA; DRUG RESISTANCE, NEOPLASM; GENE DOSAGE; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 84978134356     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9341     Document Type: Article

References (21)

1. Attard G, Parker C, Eeles RA, Schroder F, Tomlins SA, Tannock I, Drake CG, de Bono JS. Prostate cancer. Lancet. 2016; 387:70-82.
2. Zhang TY, Agarwal N, Sonpavde G, DiLorenzo G, Bellmunt J, Vogelzang NJ. Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments. Curr Urol Rep. 2013; 14:174-183.
3. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, et al. Development of a secondgeneration antiandrogen for treatment of advanced prostate cancer. Science. 2009; 324:787-790.
4. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014; 371:424-433.
5. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367:1187-1197.
6. Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, Phung D, van Os S, Hasabou N, Wang F, Bhattacharya S, Heidenreich A. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol. 2016; 17:153-163.
7. Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoshik A, Phung, Higano CS. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. J Clin Oncol. 2016 Jan 25; [Epub ahead of print].
8. Romanel A, Tandefelt DG, Conteduca V, Jayaram A, Casiraghi N, Wetterskog D, Salvi S, Amadori D, Zafeiriou Z, Rescigno P, Bianchini D, Gurioli G, Casadio V, et al. Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med. 2015; 7:312re10.
9. Diaz LA, Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014; 32:579-586.
10. Azad AA, Volik SV, Wyatt AW, Haegert A, Le Bihan S, Bell RH, Anderson SA, McConeghy B, Shukin R, Bazov J, Youngren J, Paris P, Thomas G, et al. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2015; 21:2315-2324.
11. Frenel JS, Carreira S, Goodall J, Roda D, Perez-Lopez R, Tunariu N, Riisnaes R, Miranda S, Figueiredo I, Nava-Rodrigues D, Smith A, Leux C, Garcia-Murillas I, et al. Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. Clin Cancer Res. 2015; 21:4586-4596.
12. Salvi S, Casadio V, Conteduca V, Burgio SL, Menna C, Bianchi E, Rossi L, Carretta E, Masini C, Amadori D, Calistri D, Attard G, De Giorgi U. Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. Br J Cancer. 2015; 112:1717-1724.
13. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS, Marass F, Humphray S, Hadfield J, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013; 497:108-112.
14. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013; 10:472-484.
15. Conteduca V, Aieta M, Amadori D, De Giorgi U. Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies. Crit Rev Oncol Hematol. 2014; 92:11-24.
16. Conteduca V, Burgio SL, Menna C, Carretta E, Rossi L, Bianchi E, Masini C, Amadori D, De Giorgi U. Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide. The Prostate. 2014; 74: 1691-1696.
17. Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol. 2015; 67:3-29.
18. Conteduca V, Caffo O, Fratino L, Lo Re G, Basso U, D'Angelo A, Donini M, Verderame F, Ratta R, Procopio G, Campadelli E, Massari F, Gasparro D, et al. Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. Future Oncol. 2015; 11:2881-2891.
19. Carreira S, Romanel A, Goodall J, Grist E, Ferraldeschi R, Miranda S, Prandi D, Lorente D, Frenel JS, Pezaro C, Omlin A, Rodrigues DN, Flohr P, et al. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med. 2014; 6:254ra125.
20. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014; 371:1028-1038.
21. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26:1148-1159.